IgE Fc Protein, Human, Recombinant (His) V2

一键复制产品信息

SPR兼容缓冲液

货号 TMPY-05072U

IgE Fc Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P01854-1.

IgE Fc Protein, Human, Recombinant (His) V2

一键复制产品信息

SPR兼容缓冲液

货号 TMPY-05072U

IgE Fc Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P01854-1.

规格	价格	库存
5 μg	¥ 496	6-8日内发货
10 μg	¥ 791	6-8日内发货
20 μg	¥ 1,330	5日内发货
50 μg	¥ 2,650	5日内发货
100 μg	¥ 4,470	5日内发货
200 μg	¥ 7,360	5日内发货
500 μg	¥ 14,170	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Immobilized Human Fc epsilon RI alpha, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Human IgE, His Tag with the EC50 of 2.5 ng/ml determined by ELISA. (QC Test) Immobilized Human IgE, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Omalizumab, hFc Tag with the EC50 of 5.0 ng/ml determined by ELISA.
产品描述	IgE Fc Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P01854-1.
种属	Human
表达系统	HEK293 Cells
标签	C-His
蛋白编号	P01854-1
蛋白构建	Ser106-Lys428
蛋白纯度	> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC
分子量	37.49 kDa (Predicted); 45-60 kDa (Due to glycosylation)
内毒素	< 0.1 EU/μg of the protein as determined by the LAL method.
蛋白性状	Solution
缓冲液	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
存储	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.